

AH  
CONCLD

15. The method according to claim 14, wherein said tetrazolium salt comprises MTT (3-{4,5 dimethylthiazole-2-yl}-2,5-diphenyl tetrazolium bromide).
16. The method according to claim 14, wherein said tetrazolium salt comprises XTT (2,3-bis{2-methoxy-4-nitro-5-sulfophenyl}-5-({phenyl amino}carbonyl)-2H-tetrazolium hydroxide).

IN THE ABSTRACT:

AS

In line 2 of the abstract please replace "administered to an organism" with on an individual organism without having to first administer the substance to the organism. The method allows for safe and reliable determination of the tolerance and effectiveness of xenogenic pharmaceutical products for a particular individual or animal.

REMARKS:

The amendments have been taken to modify the description, the claims and the abstract to United States practice. No new matter has been added.

THE EXAMINER IS RESPECTFULLY REQUESTED TO SEND ALL URGENT COMMUNICATIONS IN THIS CASE BY FAX. THANK YOU.

Respectfully submitted,

*Paul Vincent*

Paul J. Vincent, Reg. No. 37,461  
Agent for the Applicant  
Schuster & Partner  
Wiederholdstrasse 10  
D-70174 Stuttgart  
Germany  
Telephone: 0049-711-29 95 91  
Fax: 0049-711-29 95 94